Congestive heart failure and thromboembolism: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Patients with [[congestive heart failure]] are at an increase risk of thromboembolic events. These events include [[stroke]], [[transient ischemic attack]], [[deep vein thrombosis]] and [[pulmonary embolism]]. The risk of thromboembolism in the absence of [[atrial fibrillation]] or [[atrial flutter]] is about 1% per year. | Patients with [[congestive heart failure]] are at an increase risk of thromboembolic events. These events include [[stroke]], [[transient ischemic attack]], [[deep vein thrombosis]] and [[pulmonary embolism]]. The risk of thromboembolism in the absence of [[atrial fibrillation]] or [[atrial flutter]] is about 1% per year. [[Hypertension]] and a lower [[left ventricular ejection fraction]] were independently associated with higher rates of thromboembolism. It has been hypothesized that a lower ejection fraction may predispose patients to mural thrombosis and thereby increase the risk of thromboembolism. | ||
The incidence of thromboembolism in other trials has been reported as follows: | The incidence of thromboembolism in other trials has been reported as follows: | ||
| Line 13: | Line 13: | ||
Outside of clinical trials, and in populations in whom atrial fibrillation is present, the risk is even higher (4.1% per year in the Framingham Heart Study) | Outside of clinical trials, and in populations in whom atrial fibrillation is present, the risk is even higher (4.1% per year in the Framingham Heart Study) | ||
==Treatment and Prevention== | |||
Treatment with [[amiodarone]] or [[implantable cardiac defibrillator]] device is associated with a lower rate of thromboembolism. It has been postulated that these drugs and devices reduce the frequency of atrial fibrillation and atrial flutter and thereby reduce the risk of embolization. | |||
==References== | ==References== | ||
Revision as of 21:50, 26 April 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Epidemiology and Demographics
Patients with congestive heart failure are at an increase risk of thromboembolic events. These events include stroke, transient ischemic attack, deep vein thrombosis and pulmonary embolism. The risk of thromboembolism in the absence of atrial fibrillation or atrial flutter is about 1% per year. Hypertension and a lower left ventricular ejection fraction were independently associated with higher rates of thromboembolism. It has been hypothesized that a lower ejection fraction may predispose patients to mural thrombosis and thereby increase the risk of thromboembolism.
The incidence of thromboembolism in other trials has been reported as follows:
- Vasodilator Heart Failure Trial (V-HeFT) I 2.7% per year
- V-HeFT II 2.1% per year
Outside of clinical trials, and in populations in whom atrial fibrillation is present, the risk is even higher (4.1% per year in the Framingham Heart Study)
Treatment and Prevention
Treatment with amiodarone or implantable cardiac defibrillator device is associated with a lower rate of thromboembolism. It has been postulated that these drugs and devices reduce the frequency of atrial fibrillation and atrial flutter and thereby reduce the risk of embolization.